作者
Yongyou Zhang,Amar B. Desai,Sung Yeun Yang,Ki Beom Bae,Monika I. Antczak,Stephen P. Fink,Shruti Tiwari,Joseph Willis,Noelle S. Williams,Dawn Dawson,David N. Wald,Wei-Dong Chen,Zhenghe Wang,Lakshmi Kasturi,Gretchen LaRusch,Lucy He,Fabio Cominelli,Luca Di Martino,Zora Djurić,Ginger L. Milne,Mark R. Chance,Juan Sanabria,Chris Dealwis,Debra Mikkola,Jacinth Naidoo,Shuguang Wei,Hsin-Hsiung Tai,Stanton L. Gerson,Joseph M. Ready,Bruce A. Posner,James K. V. Willson,Sanford D. Markowitz
摘要
Agents that promote tissue regeneration could be beneficial in a variety of clinical settings, such as stimulating recovery of the hematopoietic system after bone marrow transplantation. Prostaglandin PGE2, a lipid signaling molecule that supports expansion of several types of tissue stem cells, is a candidate therapeutic target for promoting tissue regeneration in vivo. Here, we show that inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a prostaglandin-degrading enzyme, potentiates tissue regeneration in multiple organs in mice. In a chemical screen, we identify a small-molecule inhibitor of 15-PGDH (SW033291) that increases prostaglandin PGE2 levels in bone marrow and other tissues. SW033291 accelerates hematopoietic recovery in mice receiving a bone marrow transplant. The same compound also promotes tissue regeneration in mouse models of colon and liver injury. Tissues from 15-PGDH knockout mice demonstrate similar increased regenerative capacity. Thus, 15-PGDH inhibition may be a valuable therapeutic strategy for tissue regeneration in diverse clinical contexts.